Effect of metformin in addition to an antenatal diet and lifestyle intervention on fetal growth and adiposity: the GRoW randomised trial

Abstract Background The infants born to women who are overweight or obese in pregnancy are at an increased risk of being born macrosomic or large for gestational age. Antenatal dietary and lifestyle interventions have been shown to be ineffective at reducing this risk. Our aim was to examine the eff...

Full description

Bibliographic Details
Main Authors: Amanda J. Poprzeczny, Jennie Louise, Andrea R. Deussen, Jodie M. Dodd
Format: Article
Language:English
Published: BMC 2020-09-01
Series:BMC Endocrine Disorders
Subjects:
Online Access:http://link.springer.com/article/10.1186/s12902-020-00618-0
_version_ 1818878669184040960
author Amanda J. Poprzeczny
Jennie Louise
Andrea R. Deussen
Jodie M. Dodd
author_facet Amanda J. Poprzeczny
Jennie Louise
Andrea R. Deussen
Jodie M. Dodd
author_sort Amanda J. Poprzeczny
collection DOAJ
description Abstract Background The infants born to women who are overweight or obese in pregnancy are at an increased risk of being born macrosomic or large for gestational age. Antenatal dietary and lifestyle interventions have been shown to be ineffective at reducing this risk. Our aim was to examine the effects of metformin in addition to a diet and lifestyle intervention on fetal growth and adiposity among women with a BMI above the healthy range. Methods Women who had a body mass index ≥25 kg/m2 in early pregnancy, and a singleton gestation, were enrolled in the GRoW trial from three public maternity hospitals in metropolitan Adelaide. Women were invited to have a research ultrasounds at 28 and 36 weeks’ gestation at which ultrasound measures of fetal biometry and adiposity were obtained. Fetal biometry z-scores and trajectories were calculated. Measurements and calculations were compared between treatment groups. This secondary analysis was pre-specified. Results Ultrasound data from 511 women were included in this analysis. The difference in femur length at 36 weeks’ gestation was (0.07 cm, 95% CI 0.01–0.14 cm, p = 0.019) and this was was statistically significant, however the magnitude of effect was small. Differences between treatment groups for all other fetal biometry measures, z-scores, estimated fetal weight, and adiposity measures at 28 and 36 weeks’ gestation were similar. Conclusions The addition of metformin to dietary and lifestyle advice in pregnancy for overweight and obese women has no clinically relevant effect on ultrasound measures of fetal biometry or adiposity. Trial registration Australian and New Zealand Clinical Trials Registry ( ACTRN12612001277831 ).
first_indexed 2024-12-19T14:17:51Z
format Article
id doaj.art-278188535a904dc595f5bbb493062472
institution Directory Open Access Journal
issn 1472-6823
language English
last_indexed 2024-12-19T14:17:51Z
publishDate 2020-09-01
publisher BMC
record_format Article
series BMC Endocrine Disorders
spelling doaj.art-278188535a904dc595f5bbb4930624722022-12-21T20:17:55ZengBMCBMC Endocrine Disorders1472-68232020-09-012011910.1186/s12902-020-00618-0Effect of metformin in addition to an antenatal diet and lifestyle intervention on fetal growth and adiposity: the GRoW randomised trialAmanda J. Poprzeczny0Jennie Louise1Andrea R. Deussen2Jodie M. Dodd3The University of Adelaide, The Robinson Research Institute, and Discipline of Obstetrics and GynaecologyThe University of Adelaide, The Robinson Research Institute, and Discipline of Obstetrics and GynaecologyThe University of Adelaide, The Robinson Research Institute, and Discipline of Obstetrics and GynaecologyThe University of Adelaide, The Robinson Research Institute, and Discipline of Obstetrics and GynaecologyAbstract Background The infants born to women who are overweight or obese in pregnancy are at an increased risk of being born macrosomic or large for gestational age. Antenatal dietary and lifestyle interventions have been shown to be ineffective at reducing this risk. Our aim was to examine the effects of metformin in addition to a diet and lifestyle intervention on fetal growth and adiposity among women with a BMI above the healthy range. Methods Women who had a body mass index ≥25 kg/m2 in early pregnancy, and a singleton gestation, were enrolled in the GRoW trial from three public maternity hospitals in metropolitan Adelaide. Women were invited to have a research ultrasounds at 28 and 36 weeks’ gestation at which ultrasound measures of fetal biometry and adiposity were obtained. Fetal biometry z-scores and trajectories were calculated. Measurements and calculations were compared between treatment groups. This secondary analysis was pre-specified. Results Ultrasound data from 511 women were included in this analysis. The difference in femur length at 36 weeks’ gestation was (0.07 cm, 95% CI 0.01–0.14 cm, p = 0.019) and this was was statistically significant, however the magnitude of effect was small. Differences between treatment groups for all other fetal biometry measures, z-scores, estimated fetal weight, and adiposity measures at 28 and 36 weeks’ gestation were similar. Conclusions The addition of metformin to dietary and lifestyle advice in pregnancy for overweight and obese women has no clinically relevant effect on ultrasound measures of fetal biometry or adiposity. Trial registration Australian and New Zealand Clinical Trials Registry ( ACTRN12612001277831 ).http://link.springer.com/article/10.1186/s12902-020-00618-0Fetal growthFetal adiposityMaternal obesityMetforminAntenatal interventions
spellingShingle Amanda J. Poprzeczny
Jennie Louise
Andrea R. Deussen
Jodie M. Dodd
Effect of metformin in addition to an antenatal diet and lifestyle intervention on fetal growth and adiposity: the GRoW randomised trial
BMC Endocrine Disorders
Fetal growth
Fetal adiposity
Maternal obesity
Metformin
Antenatal interventions
title Effect of metformin in addition to an antenatal diet and lifestyle intervention on fetal growth and adiposity: the GRoW randomised trial
title_full Effect of metformin in addition to an antenatal diet and lifestyle intervention on fetal growth and adiposity: the GRoW randomised trial
title_fullStr Effect of metformin in addition to an antenatal diet and lifestyle intervention on fetal growth and adiposity: the GRoW randomised trial
title_full_unstemmed Effect of metformin in addition to an antenatal diet and lifestyle intervention on fetal growth and adiposity: the GRoW randomised trial
title_short Effect of metformin in addition to an antenatal diet and lifestyle intervention on fetal growth and adiposity: the GRoW randomised trial
title_sort effect of metformin in addition to an antenatal diet and lifestyle intervention on fetal growth and adiposity the grow randomised trial
topic Fetal growth
Fetal adiposity
Maternal obesity
Metformin
Antenatal interventions
url http://link.springer.com/article/10.1186/s12902-020-00618-0
work_keys_str_mv AT amandajpoprzeczny effectofmetformininadditiontoanantenataldietandlifestyleinterventiononfetalgrowthandadipositythegrowrandomisedtrial
AT jennielouise effectofmetformininadditiontoanantenataldietandlifestyleinterventiononfetalgrowthandadipositythegrowrandomisedtrial
AT andreardeussen effectofmetformininadditiontoanantenataldietandlifestyleinterventiononfetalgrowthandadipositythegrowrandomisedtrial
AT jodiemdodd effectofmetformininadditiontoanantenataldietandlifestyleinterventiononfetalgrowthandadipositythegrowrandomisedtrial